ZF 2001
Alternative Names: Coronavirus vaccine - Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology of the Chinese Academy of Sciences; COVID-2019 vaccine - Anhui Zhifei Longcom Biologic Pharmaceutical/Institute of Microbiology of the Chinese Academy of Sciences; Recombinant new coronavirus vaccine (CHO cell) - Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology of the Chinese Academy of Sciences; Recombinant novel coronavirus vaccine (CHO Cell) - Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology of the Chinese Academy of Sciences; ZF-2001; ZF-UZ-VAC 2001; ZIFIVAXLatest Information Update: 21 May 2024
At a glance
- Originator Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology of the Chinese Academy of Sciences
- Developer Anhui Zhifei Longcom Biopharmaceutical
- Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 20 May 2024 Anhui Zhifei Longcom Biologic Pharmacy completes a clinical trial for COVID-2019 infections (Prevention) in China (IM, injection) (NCT05850507)
- 25 Sep 2023 Anhui Zhifei Longcom Biopharmaceutical plans a phase I trial for COVID-2019 infections (Prevention) (IM, Injection) in September 2023 (NCT06043388)
- 06 Sep 2023 Anhui Zhifei Longcom Biopharmaceutical plans a phase II trial for COVID-2019 infections (Prevention) in China (IM) in September 2023 (NCT06025812)